Summary
- Prevail Therapeutics has filed to raise $125 million in a U.S. IPO.
- The firm is developing treatments for Parkinson's Disease and other neurodegenerative conditions.
- PRVL is still pre-Phase 1 stage; the IPO is probably more suited to long-term institutional holders comfortable with ultra-early-stage life science firms.
- Looking for a community to discuss ideas with? IPO Edge features a chat room of like-minded investors sharing investing ideas and strategies. Start your free trial today »
Quick Take
Prevail Therapeutics (PRVL) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases.
PRVL’s status is still pre-Phase 1 trial, so the IPO is an ultra-high-risk investment that is more suited to institutional investors with long timeframes for holding shares.

